Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Breast Neoplasms 9Prostatic Neoplasms 8Pancreatic Neoplasms 6Uterine Cervical Neoplasms 4Neoplasms 4Brain Neoplasms 4Triple Negative Breast Neoplasms 3Rectal Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma 3Lung Neoplasms 3Liver Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia 2Hodgkin Disease 2Glioma 2Esophageal Neoplasms 2Disease 2Colonic Neoplasms 2Carcinoma, Neuroendocrine 2Carcinoma, Hepatocellular 2Carcinoma in Situ 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Thoracic Neoplasms 1Thoracic Diseases 1Spinal Diseases 1

Interventions

Cyclophosphamide 13Prednisone 10N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 9Doxorubicin 9Vincristine 8Azacitidine 6romidepsin 5Gemcitabine 5Brentuximab Vedotin 5fludarabine 4Etoposide 4Dexamethasone 4pembrolizumab 3belinostat 3Lenalidomide 3Biopsy 310-propargyl-10-deazaaminopterin 3tazemetostat 2ruxolitinib 2ixazomib 2duvelisib 2Nivolumab 2Bendamustine Hydrochloride 2venetoclax 1tislelizumab 1thymoglobulin 1spartalizumab 1somatostatin, cyclic hexapeptide(Phe-Phe-Trp-Lys-Thr-Phe)- 1sodium-iodide symporter 1sintilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Peripheral × Magnetic Resonance Imaging × 1 year × Clear all
NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 24 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡